替加环素与利奈唑胺及其他五种抗菌药物对包括脆弱拟杆菌群在内的 332 株厌氧分离株的活性比较， , 和 种。
Activity of Tedizolid Compared to Linezolid and Five Other Antimicrobial Agents against 332 Anaerobic Isolates, Including Bacteroides fragilis Group, , , and Species.
机构信息
R. M. Alden Research Laboratory, Santa Monica, California, USA
The David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
出版信息
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01088-20.
Abstract
Tedizolid's anaerobic activity is unappreciated. In this study, it was active against all 332 anaerobic isolates tested at ≤2 μg/ml except and was more active than linezolid against group species (MIC, 1 μg/ml versus 2 to 4 μg/ml). Tedizolid was active against Gram-positive anaerobes (MIC for clostridia, 0.25 to 1 μg/ml; MIC for anaerobic cocci, ≤0.06 to 0.25 μg/ml). Our data coupled with clinical reports indicate that clinicians should consider its use in mixed infections where and anaerobes are involved.
摘要
替加环素的抗厌氧菌活性尚未被充分认识。在这项研究中，替加环素对所有检测的 332 株厌氧菌的活性均在≤2μg/ml，除了 ，并且对 组物种的活性强于利奈唑胺（MIC，1μg/ml 与 2 至 4μg/ml）。替加环素对革兰阳性厌氧菌具有活性（梭菌的 MIC 为 0.25 至 1μg/ml；厌氧球菌的 MIC 为≤0.06 至 0.25μg/ml）。我们的数据结合临床报告表明，临床医生应考虑在涉及 和厌氧菌的混合感染中使用替加环素。
相似文献
1
Activity of Tedizolid Compared to Linezolid and Five Other Antimicrobial Agents against 332 Anaerobic Isolates, Including Bacteroides fragilis Group, , , and Species.替加环素与利奈唑胺及其他五种抗菌药物对包括脆弱拟杆菌群在内的 332 株厌氧分离株的活性比较， , 和 种。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01088-20.
2
The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.替加环素对脆弱拟杆菌属的体外活性未得到充分重视，包括对甲硝唑和碳青霉烯类耐药的菌株。
Anaerobe. 2017 Feb;43:1-3. doi: 10.1016/j.anaerobe.2016.09.008. Epub 2016 Oct 3.
3
In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.新型去氟（6）喹诺酮类药物加替沙星对临床厌氧菌的体外活性
Antimicrob Agents Chemother. 2003 Nov;47(11):3667-71. doi: 10.1128/AAC.47.11.3667-3671.2003.
4
PCR-based detection of resistance genes in anaerobic bacteria isolated from intra-abdominal infections.基于 PCR 的腹腔感染分离厌氧菌耐药基因检测。
J Infect Chemother. 2013 Apr;19(2):279-90. doi: 10.1007/s10156-012-0532-2. Epub 2013 Jan 22.
5
In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.曲伐沙星对557株厌氧菌的体外活性
Antimicrob Agents Chemother. 1996 Sep;40(9):2232-5. doi: 10.1128/AAC.40.9.2232.
6
Activity of linezolid against anaerobic bacteria.利奈唑胺对厌氧菌的活性。
Int J Antimicrob Agents. 2003 Jul;22(1):28-34. doi: 10.1016/s0924-8579(03)00087-6.
7
Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.PH-027与利奈唑胺及其他抗厌氧菌抗菌药物对艰难梭菌及其他厌氧菌临床分离株的体外活性比较
J Chemother. 2003 Apr;15(2):113-7. doi: 10.1179/joc.2003.15.2.113.
8
Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds.比较头孢洛林、头孢洛林-阿维巴坦和其他抗菌药物对从感染性糖尿病足创面培养的需氧菌和厌氧菌的体外活性。
Diagn Microbiol Infect Dis. 2013 Jul;76(3):347-51. doi: 10.1016/j.diagmicrobio.2013.03.019. Epub 2013 Apr 24.
9
Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.吉米沙星对革兰氏阳性和革兰氏阴性厌氧性病原体的体外活性综述。
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:55-65. doi: 10.1093/jac/45.suppl_3.55.
10
Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.莫西沙星体外对专性厌氧菌的比较活性
Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):228-32. doi: 10.1007/s100960050465.
引用本文的文献
1
The antimicrobial activity of linezolid against unconventional pathogens.利奈唑胺对非传统病原体的抗菌活性。
PeerJ. 2025 Feb 12;13:e18825. doi: 10.7717/peerj.18825. eCollection 2025.
2
Recent Trends in Antimicrobial Resistance among Anaerobic Clinical Isolates.厌氧临床分离株中抗菌药物耐药性的最新趋势
Microorganisms. 2023 Jun 1;11(6):1474. doi: 10.3390/microorganisms11061474.
3
Antibiotic Resistance and Mechanisms of Pathogenic Bacteria in Tubo-Ovarian Abscess.输卵管卵巢脓肿中病原菌的耐药性及机制
Front Cell Infect Microbiol. 2022 Jul 27;12:958210. doi: 10.3389/fcimb.2022.958210. eCollection 2022.
4
Pharmacokinetics and Pharmacodynamics of Tedizolid.替加环素的药代动力学和药效学。
Clin Pharmacokinet. 2022 Apr;61(4):489-503. doi: 10.1007/s40262-021-01099-7. Epub 2022 Feb 7.
5
In Vitro Antimicrobial Susceptibility Profiles of Gram-Positive Anaerobic Cocci Responsible for Human Invasive Infections.引起人类侵袭性感染的革兰氏阳性厌氧球菌的体外抗菌药敏谱
Microorganisms. 2021 Aug 4;9(8):1665. doi: 10.3390/microorganisms9081665.
本文引用的文献
1
Safety and Tolerability of More than Six Days of Tedizolid Treatment.连续使用泰地唑胺超过六天的安全性和耐受性。
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00356-20.
2
The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.替加环素对脆弱拟杆菌属的体外活性未得到充分重视，包括对甲硝唑和碳青霉烯类耐药的菌株。
Anaerobe. 2017 Feb;43:1-3. doi: 10.1016/j.anaerobe.2016.09.008. Epub 2016 Oct 3.
3
In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study.替加环素对皮肤及皮肤结构感染和医院获得性肺炎患者革兰氏阳性菌的体外活性：一项韩国多中心研究。
Ann Lab Med. 2015 Sep;35(5):523-30. doi: 10.3343/alm.2015.35.5.523.
4
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.皮肤和软组织感染诊断与管理实践指南：美国传染病学会 2014 年更新版。
Clin Infect Dis. 2014 Jul 15;59(2):e10-52. doi: 10.1093/cid/ciu444.
5
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.替考拉宁治疗 6 天与利奈唑胺治疗 10 天治疗急性细菌性皮肤和皮肤结构感染（ESTABLISH-2）：一项随机、双盲、III 期、非劣效性试验。
Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5.
6
Tedizolid: a new oxazolidinone antimicrobial.特地唑胺：一种新型恶唑烷酮类抗菌药物。
Am J Health Syst Pharm. 2014 Apr 15;71(8):621-33. doi: 10.2146/ajhp130482.
7
Tedizolid: a novel oxazolidinone for Gram-positive infections.特地唑胺：一种用于革兰氏阳性菌感染的新型恶唑烷酮类药物。
Clin Infect Dis. 2014 Jan;58 Suppl 1:S1-3. doi: 10.1093/cid/cit658.
8
Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.第四次比利时多中心厌氧菌抗生素敏感性调查。
J Antimicrob Chemother. 2014 Jan;69(1):155-61. doi: 10.1093/jac/dkt344. Epub 2013 Sep 5.
9
Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.替加环素（TR-700）对不同流行病学来源的耐甲氧西林金黄色葡萄球菌（MRSA）标准菌株的活性。
Antimicrob Agents Chemother. 2013 Jun;57(6):2892-5. doi: 10.1128/AAC.00274-13. Epub 2013 Apr 9.
10
Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.磷酸替加环素与利奈唑胺治疗急性细菌性皮肤和皮肤结构感染：ESTABLISH-1 随机试验。
JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241.
Zotero 插件